Award for emerging innovator, MiReven

MiReven, a company involving the Harry Perkins Institute of Medical Research, the University of WA and the Medical Research Commercialisation Fund, has won a major category at the WA Innovator of the Year awards.

The pioneering research led by the Harry Perkins Institute’s Director Designate Professor Peter Leedman and Dr Keith Giles, into the anti-cancer potential of microRNA-7 (miR-7) won the ‘Emerging Innovation Category.’

“This is the result of an outstanding team effort over many years within the Laboratory for Cancer Medicine at the Harry Perkins Institute (formerly the WA Institute for Medical Research). The award is an acknowledgement that our cancer research is cutting edge and we hope it will progress towards the clinic in the next few years,” said Professor Peter Leedman.

The Harry Perkins Institute Director, Professor Peter Klinken, congratulated the team at miReven for their award, saying that commercialisation of medical research discoveries was vital for the translation of scientific discoveries into treatments for cancer patients.

“This wonderful achievement is only possible due to the vision and invaluable support of the Medical Research Commercialisation Fund, the University of WA and the Western Australian government,” he said.

“The investment from all stakeholders is not only helping to commercialise this great innovation, but is also supporting medical research in Australia.”

MiReven is a biopharmaceutical company focused on developing miR-7 as a cancer therapy.

Researchers from the Harry Perkins Institute have shown that miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor (EGFR), as well as its associated signalling pathways that promote cancer development.

EGFR is a major target for cancer therapy because it is often associated with disease progression, resistance to chemotherapy and radiation therapy.

The 2013 WA Innovator of the Year Awards are administered by the WA Department of Commerce.

Back To Top